SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: OmertaSoldier who wrote (19048)2/24/1999 1:28:00 AM
From: VLAD   of 23519
 
OS,

Those who have been following Zonagen and Vasoscam over the past year know that this one isn't going to get away with the hype considering:

1)Vasomax only showed a 13% improvement over placebo in Zonagen's P3 studies.

2)Vasomax just as Viagra can create hypotension which can prove fatal in the CAD patient.

3)So far in the only market that the product has been marketed in (Mexico), sales are miniscule.

I feel that as more oral drugs receive approval it will shed more and more light on the importance of a good safety profile--this is where with good domestic marketing partner, Vivus will be able to regain a lot of the market share lost to Viagra.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News